<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Liang X</submitter><funding>Hulunbuir City Science and Technology Bureau Scientific Research Program Project</funding><pagination>2054876</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8958104</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>2022</volume><pubmed_abstract>Both rs1801133 mutation on Methylenetetrahydrofolate reductase (MTHFR) gene and transcription factor peroxisome proliferator-activated gamma (PPARG) have been associated with plasma homocysteine (Hcy) levels and hypertension. However, their role in H-type hypertension remains unclear. In this study, we first tested the association between rs1801133 genotypes and Hcy level in H-type hypertension using clinical profiles collected from 203 patients before and after the treatment using enalapril maleate and folic acid tablets (EMFAT). Then, we constructed a literature-based pathway analysis to explore the role of the rs1801133-PPARG signaling pathway in H-type hypertension and its treatment. Although presented similar blood pressure, the patients with TT genotype of rs1801133 were much younger</pubmed_abstract><journal>PPAR research</journal><pubmed_title>Explore the Role of the rs1801133-PPARG Pathway in the H-type Hypertension.</pubmed_title><pmcid>PMC8958104</pmcid><funding_grant_id>2018NS021</funding_grant_id><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>He T</pubmed_authors><pubmed_authors>Liang X</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Gao L</pubmed_authors><pubmed_authors>Rong D</pubmed_authors><pubmed_authors>Wei L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Explore the Role of the rs1801133-PPARG Pathway in the H-type Hypertension.</name><description>Both rs1801133 mutation on Methylenetetrahydrofolate reductase (MTHFR) gene and transcription factor peroxisome proliferator-activated gamma (PPARG) have been associated with plasma homocysteine (Hcy) levels and hypertension. However, their role in H-type hypertension remains unclear. In this study, we first tested the association between rs1801133 genotypes and Hcy level in H-type hypertension using clinical profiles collected from 203 patients before and after the treatment using enalapril maleate and folic acid tablets (EMFAT). Then, we constructed a literature-based pathway analysis to explore the role of the rs1801133-PPARG signaling pathway in H-type hypertension and its treatment. Although presented similar blood pressure, the patients with TT genotype of rs1801133 were much younger</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-04-19T10:46:51.698Z</modification><creation>2024-10-19T09:16:56.809Z</creation></dates><accession>S-EPMC8958104</accession><cross_references><pubmed>35356087</pubmed><doi>10.1155/2022/2054876</doi></cross_references></HashMap>